HomeCompareTGMEX vs ABBV

TGMEX vs ABBV: Dividend Comparison 2026

TGMEX yields 22.30% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TGMEX wins by $137869508.07M in total portfolio value
10 years
TGMEX
TGMEX
● Live price
22.30%
Share price
$8.97
Annual div
$2.00
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$137869508.18M
Annual income
$136,692,137,921,415.10
Full TGMEX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TGMEX vs ABBV

📍 TGMEX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTGMEXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TGMEX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TGMEX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TGMEX
Annual income on $10K today (after 15% tax)
$1,895.78/yr
After 10yr DRIP, annual income (after tax)
$116,188,317,233,202.83/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, TGMEX beats the other by $116,188,317,212,146.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TGMEX + ABBV for your $10,000?

TGMEX: 50%ABBV: 50%
100% ABBV50/50100% TGMEX
Portfolio after 10yr
$68934754.14M
Annual income
$68,346,068,973,093.43/yr
Blended yield
99.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TGMEX
No analyst data
Altman Z
-0.6
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TGMEX buys
0
ABBV buys
0
No recent congressional trades found for TGMEX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTGMEXABBV
Forward yield22.30%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$137869508.18M$102.3K
Annual income after 10y$136,692,137,921,415.10$24,771.77
Total dividends collected$137791310.51M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TGMEX vs ABBV ($10,000, DRIP)

YearTGMEX PortfolioTGMEX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$15,161$4,460.65$11,550$430.00+$3.6KTGMEX
2$28,862$12,640.45$13,472$627.96+$15.4KTGMEX
3$75,863$44,980.30$15,906$926.08+$60.0KTGMEX
4$302,161$220,987.12$19,071$1,382.55+$283.1KTGMEX
5$1,968,520$1,645,208.35$23,302$2,095.81+$1.95MTGMEX
6$22,140,389$20,034,072.47$29,150$3,237.93+$22.11MTGMEX
7$444,863,531$421,173,314.86$37,536$5,121.41+$444.83MTGMEX
8$16,293,896,585$15,817,892,606.42$50,079$8,338.38+$16293.85MTGMEX
9$1,100,346,033,473$1,082,911,564,126.98$69,753$14,065.80+$1100345.96MTGMEX
10$137,869,508,177,231$136,692,137,921,415.10$102,337$24,771.77+$137869508.07MTGMEX

TGMEX vs ABBV: Complete Analysis 2026

TGMEXStock

Under normal circumstances, the fund invests at least 80% of the value of its net assets, plus any borrowings for investment purposes, in debt and equity securities issued or guaranteed by companies, financial institutions and government entities in Emerging Market Countries. It may invest in other pooled investment vehicles, including registered investment companies and collective investments not subject to registration under the 1940 Act. The fund may invest in ETFs and exchange-traded notes ("ETNs").

Full TGMEX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TGMEX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TGMEX vs SCHDTGMEX vs JEPITGMEX vs OTGMEX vs KOTGMEX vs MAINTGMEX vs JNJTGMEX vs MRKTGMEX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.